Nanological

Nanological is a CSIC spin-off developing SOMIA, a deep-tech rapid diagnostic platform designed to identify bloodstream infection pathogens directly from blood in minutes — compared to the 24–72 hours required by current culture-based workflows — without culture or molecular amplification. Its first application is sepsis, a critical unmet need where faster pathogen identification can support earlier clinical decisions and reduce reliance on broad-spectrum antibiotics. The platform combines photonics, optomechanical sensing, microfluidics and AI to capture single-cell biophysical signatures that conventional methods do not access. Early feasibility studies showed 96% classification accuracy on an initial bacterial panel in spiked human plasma. Clinical evaluation is being prepared with Hospital Ramón y Cajal in Madrid. Built on more than 10 years of CSIC research, two exclusively licensed patent families and peer-reviewed scientific publications, Nanological is developing a scalable instrument-and-cartridge platform. The team combines a scientific founding core (50+ publications, international research experience at Yale and Harvard) with a multidisciplinary execution team. Nanological is currently advancing its next stage of growth and welcomes conversations with investors and strategic partners in diagnostics and healthcare innovation.